Back to New York

S1578 • 2025

Establishes the Sickle Cell Treatment Act

Establishes the Sickle Cell Treatment Act

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor
James Sanders Jr.
Last action
2026-06-01
Official status
In Assembly Committee
Effective date
Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

Establishes the Sickle Cell Treatment Act

Establishes the Sickle Cell Treatment Act Establishes the "Sickle Cell Treatment Act" which designates sickle cell centers for excellence and outpatient treatment centers.

What This Bill Does

  • Establishes the Sickle Cell Treatment Act Establishes the "Sickle Cell Treatment Act" which designates sickle cell centers for excellence and outpatient treatment centers.

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

  1. 2026-06-01 Senate

    PASSED SENATE

  2. 2026-06-01 Senate

    DELIVERED TO ASSEMBLY

  3. 2026-06-01 Assembly

    REFERRED TO HEALTH

  4. 2026-05-28 Senate

    COMMITTEE DISCHARGED AND COMMITTED TO RULES

  5. 2026-05-28 Senate

    ORDERED TO THIRD READING CAL.1347

  6. 2026-02-04 Senate

    REPORTED AND COMMITTED TO FINANCE

  7. 2026-01-07 Assembly

    DIED IN ASSEMBLY

  8. 2026-01-07 Assembly

    RETURNED TO SENATE

  9. 2026-01-07 Senate

    REFERRED TO HEALTH

  10. 2025-05-28 Senate

    PASSED SENATE

  11. 2025-05-28 Senate

    DELIVERED TO ASSEMBLY

  12. 2025-05-28 Assembly

    REFERRED TO HEALTH

  13. 2025-05-22 Senate

    ADVANCED TO THIRD READING

  14. 2025-05-21 Senate

    2ND REPORT CAL.

  15. 2025-05-20 Senate

    1ST REPORT CAL.1217

  16. 2025-03-07 Senate

    AMEND AND RECOMMIT TO FINANCE

  17. 2025-03-07 Senate

    PRINT NUMBER 1578B

  18. 2025-02-04 Senate

    REPORTED AND COMMITTED TO FINANCE

  19. 2025-02-04 Senate

    AMEND AND RECOMMIT TO FINANCE

  20. 2025-02-04 Senate

    PRINT NUMBER 1578A

  21. 2025-01-10 Senate

    REFERRED TO HEALTH

Official Summary Text

Establishes the Sickle Cell Treatment Act
Establishes the "Sickle Cell Treatment Act" which designates sickle cell centers for excellence and outpatient treatment centers.

Current Bill Text

Read the full stored bill text
S T A T E   O F   N E W   Y O R K
        ________________________________________________________________________

                                          1578

                               2025-2026 Regular Sessions

                                    I N  S E N A T E

                                    January 10, 2025
                                       ___________

        Introduced by Sens. SANDERS, ASHBY, CLEARE, COMRIE, FERNANDEZ, GIANARIS,
          JACKSON,  KRUEGER, MAY, MAYER, MYRIE, PARKER, RAMOS, ROLISON, SEPULVE-
          DA, WEBB -- read twice and ordered printed, and  when  printed  to  be
          committed to the Committee on Health

        AN  ACT  to amend the public health law, in relation to establishing the
          "Syd O. Sotillo Sickle Cell Treatment Act"

          THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
        BLY, DO ENACT AS FOLLOWS:

     1    Section  1.  Short  title. This act shall be known and may be cited as
     2  the "Syd O. Sotillo Sickle Cell Treatment Act".
     3    § 2. The public health law is amended by adding a new section  2807-bb
     4  to read as follows:
     5    § 2807-BB. SICKLE CELL CENTERS FOR EXCELLENCE AND OUTPATIENT TREATMENT
     6  CENTERS.  1.  CENTERS  FOR SICKLE CELL CARE EXCELLENCE. THE COMMISSIONER
     7  SHALL DESIGNATE FIVE GENERAL HOSPITALS OR HOSPICES UNDER  ARTICLE  FORTY
     8  OF THIS CHAPTER, UPON SUCCESSFUL APPLICATION, AS CENTERS FOR SICKLE CELL
     9  CARE  EXCELLENCE.  THE DESIGNATIONS SHALL BE MADE THROUGH AN APPLICATION
    10  DESIGNED BY THE DEPARTMENT, AND BASED ON  SERVICE,  STAFFING  AND  OTHER
    11  CRITERIA  AS  DEVELOPED  BY  THE COMMISSIONER. THE CENTERS OF EXCELLENCE
    12  SHALL PROVIDE SPECIALIZED SICKLE CELL DISEASE CARE,  TREATMENT,  PALLIA-
    13  TIVE  CARE, EDUCATION AND RELATED SERVICES AND SHALL CONDUCT SPECIALIZED
    14  RESEARCH INTO THE CARE, TREATMENT AND MANAGEMENT OF SICKLE CELL DISEASE.
    15  DESIGNATION AS A CENTER FOR SICKLE CELL CARE EXCELLENCE SHALL NOT  ENTI-
    16  TLE  A CENTER TO ENHANCED REIMBURSEMENT, BUT MAY BE UTILIZED IN OUTREACH
    17  AND OTHER PROMOTIONAL ACTIVITIES.  EACH  CENTER  FOR  SICKLE  CELL  CARE
    18  EXCELLENCE  SHALL  AFFILIATE  AND COOPERATE WITH MAJOR CENTERS OF HIGHER
    19  LEARNING, INCLUDING MEDICAL COLLEGES, AND LIFE SCIENCE  RESEARCH  INSTI-
    20  TUTES  IN  THE STATE.  THE STATE UNIVERSITY SHALL ENTER INTO APPROPRIATE
    21  LEGAL AGREEMENTS TO ENABLE THIS COOPERATION. EACH CENTER FOR SICKLE CELL
    22  CARE EXCELLENCE SHALL RECEIVE FOUR HUNDRED  THOUSAND  DOLLARS  PER  YEAR

         EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD01146-02-5
        S. 1578                             2

     1  FROM  THE  DEPARTMENT, FROM AMOUNTS APPROPRIATED FOR THAT PURPOSE, TO BE
     2  USED ON SICKLE CELL DISEASE RESEARCH.
     3    2.  OUTPATIENT TREATMENT CENTERS. THE COMMISSIONER SHALL DESIGNATE TEN
     4  HOSPITALS, DISTRIBUTED BASED ON SICKLE CELL PATIENT  POPULATION  CONCEN-
     5  TRATIONS,  AS  SICKLE  CELL  OUTPATIENT  TREATMENT  CENTERS  WHICH SHALL
     6  PROVIDE PATIENTS TREATMENT FOR SICKLE CELL  DISEASE  AS  AN  OUTPATIENT.
     7  EACH  SICKLE  CELL OUTPATIENT TREATMENT CENTER SHALL RECEIVE TWO HUNDRED
     8  THOUSAND DOLLARS PER YEAR FROM THE DEPARTMENT, FROM AMOUNTS APPROPRIATED
     9  FOR THAT PURPOSE, TO BE USED TO ENSURE THE PROPER MANAGEMENT AND  EQUIP-
    10  PING OF THE CENTERS TO CARE FOR SICKLE CELL PATIENTS.
    11    §  3. Subdivision 8 of section 3331 of the public health law, as added
    12  by section 7-a of part D of chapter 57 of the laws of 2018,  is  amended
    13  to read as follows:
    14    8.  No  opioids  shall  be prescribed to a patient initiating or being
    15  maintained on opioid treatment for pain which has lasted more than three
    16  months or past the time of normal tissue  healing,  unless  the  medical
    17  record contains a written treatment plan that follows generally accepted
    18  national  professional  or  governmental guidelines. The requirements of
    19  this paragraph shall not apply in the case of  patients  who  are  being
    20  treated  for cancer OR SICKLE CELL DISEASE that is not in remission, who
    21  are in hospice or other end-of-life care, or whose pain is being treated
    22  as part of palliative care practices.
    23    § 4. This act shall take effect immediately.